Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 7-8, 2010, Pages 290-293

  Wrigley, Benjamin J ^a   Tapp, Luke D ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Percutaneous coronary intervention; Stenting

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROTON PUMP INHIBITOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CONSENSUS DEVELOPMENT; CORONARY STENT; DRUG ELUTING STENT; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; STENT THROMBOSIS; STOMACH PROTECTION; STROKE; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 77955904700     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.949     Document Type: Review

References (19)

1. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007; 6: 981-993.
2. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26: 2422-2434. (Pubitemid 41552972)
3. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010; 103: 13-28.
4. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet. 1996; 30: 300-313.
5. Bassand JP, Hamm CW, Ardissino D, et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. Rev Port Cardiol. 2008; 27. 1063-1143. Portugese.
6. Karjałainen PP, Vikman S, Niemela M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J. 2008; 29: 1001-1010.
7. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006; 114: 1380-1387. (Pubitemid 44462663)
8. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369: 907-919.
9. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009-1019.
10. Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2009; 119: 687-698.
11. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
12. Rogacka R, Chieffo A, Michev I, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv. 2008; 1: 56-61
13. What is the Optimal antiplatElet and anticoagulant in patients with oral anticoagulation and StenTing (WOEST) study? http://www.clinicaltrials.gov/ct2/ show/NCT00769938?2008. Accessed October 8, 2008.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
15. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78: 412-421. (Pubitemid 41393676)
16. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008; 99: 295-304.
17. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest. 2010 Mar 18. (Epub ahead of print).
18. Rubboli A, Halperin JL. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Thromb Haemost. 2008; 100: 752-753.
19. Roldán V, Marín F. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. Thromb Haemost. 2008; 100: 754-755.